Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
American Journal of Gastroenterology
Results: Out of 4,015 colonoscopic encounters, 352 patients satisfi ed the inclusion criteria for the study. Th ere were 47.1% African Americans, 45.7% Hispanics, 5.5% Caucasians, and 1.7% others. Th e mean age for the cohort was 63.3 years (SD 10.2). Th ere were no signifi cant diff erences in the demographics among the three groups. Group A, B, and C included 210, 94, and 48 patients, respectively. Th e bowel preparation was rated as poor in 46.6% of A, 52.1% of B, and 50% of C (p=0.6). ADR was 24.3% in A, 20.2% in B, and 27.1% in C (p=0.6). AADR was 12.9% in A, 11.7% in B, and 18.8% in C (p=0.4). Th ere was no statistically signifi cant diff erence in ADR and AADR among the groups on accounting for bowel preparation. Conclusion: Th e level of control of diabetes may have no impact on the quality of bowel preparation, adenoma detection rate, and advanced adenoma detection rate. Larger studies are warranted to validate these fi ndings.
International Journal of Case Reports and Images, 2017
International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties. Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations. IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.
Diseases of the Colon & Rectum, 1986
European review for medical and pharmacological sciences, 2009
Amyloidosis is a rare disease caused by extracellular deposits of insoluble fibrillar proteins in various organs and tissues. There are different forms of amyloidosis distinguished by the type of protein fibrils, by the sites of deposition and by associated conditions. Gastrointestinal involvement is common both in primary and secondary amyloidosis, while isolated gastrointestinal amyloidosis is rare. We describe a case of AL amyloidosis with a gastrointestinal involvement and restrictive cardiomiopathy. A 64 year old woman came to our attention with a history of chronic diarrhoea and weight loss, associated with dysphagia, dry mouth, xerophtalmia, chronic gastritis and depression. Clinical diagnosis has been difficult because of aspecificity of symptoms that mimed other more common diseases, like gastro-paresis, epigastric discomfort, gastric or duodenal ulcers, perforation, malabsorption, intestinal pseudo-obstruction. There is an important risk of misunderstanding and diagnostic ...
Inflammatory Bowel Diseases, 2001
Background: Amyloidosis (A) is a well-known but rare complication to inflammatory bowel disease (IBD). We describe 18 patients with IBD and A, with special emphasis on clinicopathologic features and site relationships, comparing our results with previously reported cases in the world literature. Methods: Patient records were collected from the files of the medical department at Rikshospitalet. Clinical data were compiled from records. Results: Fifteen of the 18 patients had Crohn's disease (CD), 1 had ulcerative colitis (UC), one had UC preceding CD, and 1 had indeterminate colitis. There was a male preponderance of 13:5 ס 2.6. Five of the patients had A at the time of diagnosis of IBD. Median time from diagnosis of IBD to A was 4 years, and A was diagnosed within 5 years after onset of IBD in 11 patients. Thirteen of the patients had suppurative complications; 12 had extraintestinal manifestations. Sixteen of the patients had been treated by bowel resection, 14 due to refractory IBD. Ten patients had been treated by renal transplantation. After 15 years of follow-up, the survival rate was 60%. Conclusions: Our findings strengthen the previous impression of an approximately 3-fold increased preponderance in males, with at least 10-fold increased frequency in CD compared with UC, and with a possible relationship to suppurative complications and extraintestinal manifestations, as well as an increased risk of having a bowel resection. The increased survival seems to be due to the introduction of renal transplantation.
BMJ case reports, 2011
Amyloidosis occurs as a result of the extracellular deposition of protein fibrils in organs and tissues, thus causing mild to severe pathophysiological changes. The gastrointestinal tract is a common site of amyloid deposition. While intestinal amyloidosis frequently results in polypoid lesions, ulcerations, nodules and petechial mucosal haemorrhage, tumour-like lesions are rarely developed and infrequently diagnosed before the resection because of the difficulty in differentiating them from colon cancer. The authors herein reported a case of intestinal amyloid A amyloidosis with a complication of a tumour-like lesion endoscopically resembling a malignant lesion, which was completely diminished after 1 month of observation with bowel rest. Such conservative treatment is a feasible option to cure intestinal tumour-like lesions in patients with intestinal amyloidosis when no neoplastic change is histologically detected, possibly decreasing the need for surgery of the fragile mucosa.
IOSR Journals , 2019
Amyloidosis of the Gastrointestinal tract with biopsy proven disease is rare. We present the clinical and histopathological features of localised intestinal amyloidosis with a rare case report. The patient had nonspecific gastrointestinal symptoms including haematochezia. Prior to treatment, the patient was suspected of having colo-colic intussusception on the basis of CT scan findings. The patient was treated with right hemicolectomy for caecal mass. The postoperative pathological diagnosis determined the lesion to be deposition of amyloid material with no evidence of malignancy. It was confirmed on congo red staining. Localised gastrointestinal amyloidosis is rare in incidence, but it should be considered in differential diagnosis of gastrointestinal tumours and confirmation can be done on biopsy. Although the condition is benign, there is a tendency of recurrence as suggested by literature.
Revista Espanola De Enfermedades Digestivas, 2022
Journal of Crohn's and Colitis, 2016
Background and Aims: Amyloidosis is a rare complication of inflammatory bowel disease [IBD]; its low prevalence has hindered both descriptive and therapeutic studies. The aim of this study was to estimate the prevalence of amyloidosis in IBD and the risk factors associated with this complication. Methods: This paper presents an observational study, followed by a systematic review of the epidemiological and clinical characteristics of the disease and a review of the diagnostic and therapeutic options. Results: The prevalence of amyloidosis among IBD patients is 0.53% (95% confidence interval [CI]: 0.32-0.75), although epidemiological data suggest that it may be under-diagnosed. The phenotype most frequently associated with amyloidosis is males with aggressive and extensive Crohn's disease, fistulising behaviour, perianal disease, and extra-intestinal complications, with the development of proteinuria and renal failure. Conclusions: Identifying risk factors of amyloidosis in IBD patients and screening for proteinuric renal dysfunction are useful to improve diagnostic accuracy. Referral of biopsies to a tertiary centre should also be considered, to improve diagnostic accuracy. Although there is no reliable evidence on the effectiveness of treatment, it seems reasonable to treat the underlying disease with potent immunosuppression to minimise inflammatory activity, thereby switching off amyloidogenesis.
Annals of Medical Research, 2019
Systemic amyloidosis is a rare disease characterized by extracellular accumulation of amyloid protein in one or more organs. In patients with systemic amyloidosis, the most frequently affected organs are kidney and heart, followed by the nervous system, soft tissues, and lungs. Small bowel and liver involvement are also frequent in systemic amyloidosis. Gastrointestinal (GI) findings are common, and the degree of organ involvement determines the symptoms. Patients usually have nonspecific findings such as abdominal pain, nausea, diarrhea, and dysphagia, which may delay the appropriate diagnosis. Liver involvement occurs in the majority of patients, but the symptoms typically do not happen unless a marked hepatic amyloid deposition occurs. Diagnosis is by tissue biopsy. Treatment and prognosis depend on the underlying disease. GI system involvement is a sign of poor prognosis. In this case series, five patients who were diagnosed with gastrointestinal system amyloidosis in our clinic are presented.
The Egyptian Journal of Internal Medicine
Amyloidosis is a rare condition where fibrillar proteins and abnormal, soluble peptides accumulate throughout the body’s organs. Gastrointestinal symptoms secondary to amyloid deposition vary widely and may be confused with other common small intestine diseases, making the diagnosis challenging. Our case is a 63-year-old male with a past medical history of smoking who showed up in the ED with 5 months of diffuse abdominal pain referred to the back. Pelvis-abdominal ultrasound showed bilateral acute pyelonephritis. A colonoscopy revealed large multiple ileal ulcers about 10 cm from the ileocecal valve with a wide base. Pathology biopsies revealed ileal amyloidosis and chronic ileitis with superficial erosions. The patient has been diagnosed with primary localized ileal AL amyloidosis. The patient has finally been referred for surgical resection. We want to raise awareness of ileal amyloidosis and emphasize the importance of considering uncommon etiologies of small intestine pathology...
Annals of Gastroenterology, 2017
Background Secondary systemic amyloidosis (SSA) is a rare but severe complication of inflammatory bowel disease (IBD). We aimed to evaluate the clinical characteristics, predictors of complications, and in-hospital mortality of patients with Crohn's disease (CD) and Ulcerative colitis (UC) who develop SSA. Methods Using the National Inpatient Sample, we identified patients hospitalized for IBD and SSA between 2004 and 2012. Using multivariate logistic regression, patients with CD were compared with those with UC regarding the presence or absence of SSA. IBD patients without SSA were matched in a 2:1 ratio with those with SSA using propensity matching. We analyzed the hospitalization trends of SSA in CD and UC patients using Pearson's χ 2 test. Analyses were performed using SAS version 9.3. Results Among the 302,548 patients with CD and 174,057 patients with UC hospitalized between 2004 and 2012, we identified 47 (0.02%) and 36 (0.02%) cases of SSA, respectively. We noted rising annual hospitalization trends for both CD and UC patients with or without SSA. In-hospital mortality was significantly higher for both the UC+SSA group (16.7% vs. 2.1%, P<0.0001) and the CD+SSA group (6.4% vs. 1.0%, P=0.0001) before propensity matching. However, this difference was not seen for either UC+SSA (17.1% vs. 7.1%, P=0.11) or CD+SSA (6.8% vs. 2.3%, P=0.20) after matching. Conclusions SSA rarely affects IBD patients, but when it does, it is associated with increased rates of infection, severe sepsis, and multi-organ system involvement. Despite this, SSA does not affect in-hospital mortality in IBD patients. Further studies are needed to explore this association.
Digestive Diseases and Sciences
Introduction Amyloidosis is an uncommon disease caused by the deposition of amyloid fibrils in tissues. This disease does not usually require surgical intervention, which could be warranted in the presence of complications such as bleeding, obstruction, or perforation. We present a case of primary amyloidosis of the colon in a patient affected by polymyositis who underwent Hartmann's procedure after a spontaneous colonic perforation. After 2 months of well-being, the patient underwent two consecutive surgical procedures for stenosis of the ostomy orifice. Areas Covered A review of the literature has been performed, gathering case reports highlighting the distribution of this disease by age, gender, location, and treatment when available. Expert Commentary Gastrointestinal amyloid disease is a rare condition, and it could be considered among the rare causes of intestinal perforation. Timely surgical management is often necessary.
Journal of Crohn's and Colitis, 2010
Background: Systemic amyloidosis is a rare but life-threatening complication of inflammatory bowel disease (IBD), most cases being reported among Crohn's disease (CD) patients. The only two available retrospective studies showed a prevalence ranging from 0.9% to 3% among CD patients. Aims: To evaluate the prevalence of secondary systemic amyloidosis in a large IBD cohort of a referral centre, and to describe its clinical characteristics and outcome. Methods: Patients diagnosed with amyloidosis were identified among 1006 IBD patients included in the IBD database of our centre, and their medical records were carefully reviewed. Results: Among a total of 1006 IBD patients, 5 cases of amyloidosis were identified, all of them with CD, resulting in a prevalence of 0.5% for IBD and 1% for CD. Two patients died after developing renal failure. Two patients were treated with anti-TNF agents, showing a clinical improvement of their amyloidosis. Conclusions: Secondary amyloidosis occurs mainly in long-lasting, complicated, Crohn's disease and seems to be as prevalent among IBD patients as previously reported.
World Journal of Gastroenterology, 2010
The involvement of the small bowel in systemic forms of amyloidosis may be diffuse or very rarely focal. Some cases of focal amyloidomas of the duodenum and jejunum without extraintestinal manifestations have been reported. The focal amyloidomas consisted of extensive amyloid infiltration of the entire intestinal wall thickness. Radiological barium studies, ultrasound and computed tomography (CT) patterns of diffuse small bowel amyloidosis have been described: the signs are non-specific and may include small-bowel dilatation, symmetric bowel wall thickening, mesenteric infiltration, and mesenteric adenopathy. No data are available about the positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) patterns of intestinal amyloidosis. We report two cases of small bowel amyloidosis: the former characterized by focal deposition of amyloid proteins exclusively within blood vessel walls of the terminal ileum, the latter characterized by diffuse intestinal involvement observed on MRI and PET/CT studies.
The American Journal of Gastroenterology, 2000
patients without cirrhosis (median, 3.95 ng/ml; range, 3.38 -7.01 ng/ml), or with cirrhosis (median, 6.08 ng/ml; range, 5.13-8.91 ng/ml). The highest levels of sFas were found among PSC patients (median, 11.62 ng/ml; range, 4.55-17.69 ng/ml). sFasL was never detected in patients or controls, except for one PBC patient (0.359 ng/ml at baseline). We could not find any correlation between sFas baseline levels and other biological parameters (blood levels of hyaluronic acid, alkaline phosphatase, albumin, IgG and IgM, prothrombin time, and platelet counts) or histological stage. Soluble Fas levels could not predict the response to therapy neither, because they were not different between patients with complete response to UDCA therapy, defined by normalization of liver enzymes, and those who did not respond. Nevertheless, a slight, albeit significant, decrease in sFas levels was observed after therapy, evaluated for the 19 patients with a second serum available : median sFas: 5.46 ng/ml (range, 1.63-17.56 ng/ml) at baseline versus 4.71 ng/ml (range, 2.10 -8.62 ng/ml) after treatment (p ϭ 0.036). Again, no correlations were found between the decrease in sFas levels and the response to therapy.
Gastrointestinal Endoscopy, 2004
Amyloidosis is characterized by the deposition of amyloid proteins in various tissues and organs. 1 Although GI involvement is common, clinical manifestations are highly variable. 2 Although it usually does not cause symptoms, GI involvement may manifest as malabsorption, motility disorders, pseudotumor, intestinal perforation, and GI bleeding. 2-13 Rarely, GI bleeding is massive and can be fatal. 3-10 However, the diagnosis of GI amyloidosis is difficult because of the variable clinical manifestations and the nonspecific nature of endoscopic findings. Reported here is the case of a 51-year-old man with GI amyloidosis that manifested as massive bleeding from the small bowel and was controlled at surgery with the aid of intra-operative enteroscopy. CASE REPORT A 51-year-old man was referred with a 4-hour history of massive hematochezia. The patient had developed hypovolemic shock and received blood transfusions at another hospital. He had been in good health until 4 months earlier when he experienced 3 episodes of small amounts of hematochezia. At that time, colonoscopy at his primary hospital revealed no apparent abnormality except for an cecal polyp that was removed by polypectomy. The patient also had noted a recent 10-kg weight loss, anorexia, and mild nausea. He denied other symptoms such as abdominal pain, diarrhea, constipation, malaise, low back pain, and fever. He did not smoke tobacco or drink alcohol. There was no history of tuberculosis, rheumatoid arthritis, hepatitis, diabetes mellitus, or collagen-vascular disease. His family history was non-contributory. At admission, the patient looked pale, poorly nourished, and in acute distress. Blood pressure was 120/80 mm Hg and pulse rate 100 beats per minute. Examination was unremarkable; the abdomen was soft, non-tender, and without palpable mass or hepatosplenomegaly. Laboratory data at admission included the following: Hb 8.5 g/dL (normal: 13-17 g/dL), serum total protein 6.5 g/dL (6.0-8.0 g/
Open Journal of Hematology, 2014
Introduction: Primary systemic amyloidosis is the most common form of systemic amyloidosis. Clinical presentation commonly involves organs such as the kidney and heart. We report on a patient with systemic amyloidosis presenting as intractable diarrhoea. Numerous investigations had to be done before the diagnosis could be made highlighting the challenge in making a diagnosis due to the slow progression of the disease. This report is to increase awareness among physicians of this diagnosis and to emphasise the importance of identifying patients quickly. Case Presentation: A 63 year old male was admitted with a six months history of intractable, watery diarrhoea, anorexia and progressive renal failure. He had been investigated for proteinuria and deranged renal function prior to admission but no therapy was suggested and the diagnosis at that time was inconclusive. Extensive laboratory and radiological investigations were done. The diagnosis of systemic amyloidosis was made on serum free light chains which showed excess lambda chains and a terminal iliac and colonic biopsy which revealed eosinophilic thickening of the blood vessels with positive Congo red stain. Unfortunately the patient died prior to definitive management for the amyloidosis. Conclusion: This case emphasises the importance of early recognition of systemic amyloidosis so that management can be instituted.
Summary. Inflammatory Bowel Disease (IBD), which includes both Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal manifestations (EIMs) are common in patients with IBD, and occur in 6%-47% of patients with CD or UC. EIMs can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract, and kidneys. Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complications of IBD, secondary amyloidosis (AA-type, AAA) is a rare but serious complication. Renal amyloidosis has been proven to be the most common lethal manifestation of IBD-associated amyloidosis, since renal involvement rapidly leads to end-stage renal failure. A few studies suggest that AAA is more prevalent in CD than in UC, mainly occurring in male patients with an extensive, long-lasting, and penetrating disease pattern. The therapeutic approaches of IBD-associated AAA are based both on control of the chronic inflammatory process that causes the production and storage of serum amyloid A (SAA), which is a precursor of the amyloid, as well as on destabilizing amyloid fibrils so that they can no longer maintain their β-pleated sheet configuration; however, in patients with end-stage renal disease, the only therapeutic options still available are hemodyalisis and renal transplantation. Whether effective treatment exists for AAA remains controversial.
2003
Since amyloidosis was first described in 1886, an enormous amount of literature has been published. In most patients with systemic amyloidosis, the entire gastrointestinal tract is involved. The clinical manifestations vary from asymptomatic, impaired motor activity, bleeding, perforation to death. Patel et al first reported a case of small bowel diverticula caused by amyloidosis in 1993 (1). Intestinal perforation is a very rare complication of amyloidosis and previous reports have suggested a poor prognosis (2-6). CASE REPORT A 91-year-old black female was admitted with the chief complaint of palpitations. She had no chest pain, no shortness of breath, no nausea or vomiting, no diaphoresis, and no previous episodes of this ever happening. The patient had some weakness for the last two to three weeks, malaise, and fatigue that had progressively gotten worse. She had questionable hypertension, and she was taken off of blood pressure medication seven years ago. She had a laparotomy for possible bowel obstruction 60 years ago. On physical examination she was a thin black female in no apparent distress. Respiratory and cardiovascular examinations were normal; the abdomen was soft with no tenderness, and the bowel sounds were normal. Rectal examination revealed hemepositive stools. Laboratory studies revealed the following values: hemoglobin, 5.1 g/dl, hematocrit 17.8%; normal BMP except for a potassium of 3.1, total protein 6.1 g/dl, albumin 3.2 g/dl, serum iron 6 µg/dl, total iron binding capacity 371 µg/dl, and ferritin 8.6 ng/ml. Results of the urinalysis showed no Manuscript
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.